42 results
Thumbnail

D1.103 - Two cases of discrepancy between fractional exhaled nitric oxide and airway eosinophils in asthma

Thumbnail

D1.104 - Severe Bronchial Asthma Phenotypes in a Referral Tertiary Center in Saudi Arabia

Thumbnail

D1.105 - Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy

Thumbnail

D1.106 - Grape polyphenols reduce the concentration of LPS in patients with asthma

Thumbnail

D1.107 - Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19

Thumbnail

D1.108 - Grape polyphenols increase the concentration of BPI in asthma patients who have had SARS-CoV-2

Thumbnail

D1.109 - Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy

Thumbnail

D1.110 - Analysis of clinical and anamnestic risk factors of bronchial asthma in children

Thumbnail

D1.111 - Improving severe asthma through psychological management of traumatic life events

Thumbnail

D1.112 - Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden

Thumbnail

D1.113 - Severe Asthma and Depression: the Overlooked Burden

Thumbnail

D1.114 - The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden

Thumbnail

D1.115 - Post-emergency asthma management

Thumbnail

D2.167 - Effect of Metformin on allergen specific immunotherapy

Thumbnail

D2.169 - Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children

Thumbnail

D2.174 - Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT

Thumbnail

D2.179 - Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study

Thumbnail

D2.168 - Systemic reactions to subcutaneous immunotherapy in children

Thumbnail

D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season

Thumbnail

D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment